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Introduction
Severe acute respiratory syndrome (SARS) is caused by a
newly discovered coronavirus, SARS coronavirus (SARS-CoV)
(1,2). From November 1, 2002 to June 18, 2003, a total of
8465 probable SARS cases were reported to the World Health
Organization from 29 countries, and 801 people died from this
disease. The case–fatality proportion was  10%. Although the
spread of the virus has been averted, the re-emergence of
SARS is still in question (3–6).
Like other related coronaviruses, SARS-CoV is an envelo-
ped virus containing single-stranded RNA of positive polarity.
Coronaviruses have the largest genomes known ( 30 kb)
among RNA viruses [7]. The genome of SARS-CoV com-
prises one open reading frame (ORF) encoding two overlap-
ping replicase polyproteins, polyprotein-1a (pp1a,  450 kDa)
and poplyprotein-1ab (pp1ab,  750 kDa), responsible for
virus replication (7). The rest of the genome comprises at least
five ORFs encoding structural proteins and other genes with
putative functions (8,9). Proteolytic processing, especially the
processing of replicase polyproteins, is one of the crucial
steps in the life cycle of many positive-stranded RNA viruses,
including coronaviruses. All coronaviruses encode a papline-
like protease (PLP) and a chymotrypsin-like (3CLPro) protease
for proteolytic procession during virus maturation (10).
Studies on other coronaviruses have shown that the PLP protein
cleaves at no less than two sites on the pp1a polyprotein and
that the 3CLPro protease cleaves at least 11 inter-domain sites
on the pp1a and pp1ab polyproteins [7]. Thus, the 3CLPro
protease of SARS-CoV has been considered as an important
molecular target for anti-SARS-CoV drug discovery and
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SARS-CoV is the causative agent of severe acute respiratory syndrome (SARS). The virally encoded 
3C-like protease (3CLPro) has been presumed critical for the viral replication of SARS-CoV in infected
host cells. In this study, we screened a natural product library consisting of 720 compounds for inhibitory
activity against 3CLPro. Two compounds in the library were found to be inhibitive: tannic acid (IC50  
3  M) and 3-isotheaflavin-3-gallate (TF2B) (IC50   7  M). These two compounds belong to a group
of natural polyphenols found in tea. We further investigated the 3CLPro-inhibitory activity of extracts from
several different types of teas, including green tea, oolong tea, Puer tea and black tea. Our results indi-
cated that extracts from Puer and black tea were more potent than that from green or oolong teas in their
inhibitory activities against 3CLPro. Several other known compositions in teas were also evaluated for
their activities in inhibiting 3CLPro. We found that caffeine, ( )-epigallocatechin gallte (EGCg),
epicatechin (EC), theophylline (TP), catechin (C), epicatechin gallate (ECg) and epigallocatechin (EGC)
did not inhibit 3CLPro activity. Only theaflavin-3,3 -digallate (TF3) was found to be a 3CLPro inhibitor.
This study has resulted in the identification of new compounds that are effective 3CLPro inhibitors.
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*These authors contributed equally to this work.developments. In this study, after screening of a natural
product library and further confirmation, we found that SARS-
3CLPro could be inhibited by compounds that are abundant in
teas. We also examined crude extracts from various teas and
a panel of representative natural products in teas for their
inhibitory activities against SARS-3CLPro.
Methods
Preparation of SARS-CoV 3CLPro
Total RNA extracted from a throat swab of a SARS patient
was provided by the Center for Disease Control (CDC), Taipei,
Taiwan. All RNA samples were handled under bio-safety level 2
(BSL2) regulations. Two primers, 5 -GGCGGAATTCGCCTC-
TACCAACCACCACAGA-3  and 5 -GGCGGAATTCA AAG-
CATCCAATGATGAGTGCC-3 , were used for reverse
transcription–polymerase chain reaction (RT–PCR) to synthesize
the cDNA of SARS-3CLPro using Ready-to-Go RT–PCR Beads
(Amersham Biosciences, Piscataway, NJ) according to the man-
ufacturer’s protocol. The PCR cycle used for the amplification of
cDNA of SARS-3CLProwas as follows:94 C for 5 min,25 cycles
of 94 C for 1 min, 58 C for 3 min, 72 C for 2 min and 72 C for
10 min. A full-length 3CLPro of SARS coronavirus was success-
fully expressed in Escherichia coli as a glutathione S-transferase
(GST) fusion protein. Following cleavage by thrombin, 3CLPro
was purified to homogeneity. A 15mer peptide with sequence
H2N-SITSAVLQSGFRKMA-COOH corresponding to an auto-
cleavage site of the SARS-3CLPro was synthesized and used for
protease cleavage activity assay. The highly purified protein was
shown by high-performance liquid chromatography (HPLC)
analysis to exhibit proteolytic activity in trans.
Compound Collection
The Pure Natural Products Library used to screen for 3CLPro
inhibition was obtained from MicroSource Discovery Systems,
Inc., Gaylordsville, CT. It consists of a unique collection of 720
pure natural products. The collection includes simple and com-
plex oxygen heterocycles, alkaloids, sequiterpenes, diterpenes,
pentacyclic triterpenes, sterols and many other diverse repre-
sentatives. Initially, 10 different compounds were pooled, and
the mixtures were tested for their inhibitory activities against
SARS-3CLPro. Positive pools were then deconvoluted and sin-
gle pure compounds that were able to inhibit  50% of peptide
cleavage at 10  M were scored as hits. Other compounds were
obtained from Sigma (St Louis, MO). Theaflavin (TF1), TF2
[a mixture of TF-2A (theaflavin-3-gallate) and TF-2B
(theaflavin-3 -gallate)] and theaflavin-3,3 -digallate (TF3)
were kind gifts from Dr Yu-Chih Liang, School of Medical
Technology, Taipei Medical University, Taipei, Taiwan, ROC.
Preparation of Crude Extracts from Oolong Tea,
Green Tea, Black Tea and Puer Tea
Tea liquors were prepared from oolong tea, green tea, black tea
and Puer tea (also called pu-er or pu-erh) samples as 2% (w/v) tea
solutions. The water extracts of four different types of tea leaves
were prepared by shaking for 10 min in boiling hot water in ther-
mal flasks. The extracts were then filtered through a Millex-GS
0.22  m filter (Millipore, Malsheim, France) to remove particu-
late matter. The water extracts were then evaporated under
reduced pressure to obtain viscous masses. These materials were
evaluated for their inhibitory activities against SARS-3CLPro.
Inhibition of Protease Activity of SARS-3CLPro by
HPLC Assay
A general cysteine protease inhibitor, N-ethylmaleimide (NEM,
protease inhibitor as positive control), was obtained from
Sigma (St Louis, MO). This compound was tested for its inhi-
bitory activities against SARS-3CLPro in the peptide cleavage
assay. The activities of the proteases were measured in the
absence or presence of different concentrations of these general
inhibitors. The enzyme (2  M) was pre-incubated with chemi-
cals for 30 min. Peptide was then added at 100  M to the
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Figure 1. Flowchart of the screening of the compound library and tea
compositions.reaction, and mixtures were incubated at 37 C for 1 h. The
potency of the inhibitors was calculated. The HPLC 
analysis condition is: a C18 RP guard column (250   4.6 mm  
5  m,Agilent Zorbax Extend). This method was chosen because
it gave the best resolution among several methods that were
tested. The column temperature was ambient, and the elution
(0.8 ml/min) was performed using a solvent system comprising
solvents A [10 MM NH4OAc, 0.1% trifluoroacetic acid (TFA)]
and B (acetonitrile, 0.1% TFA) mixed using a gradient starting
with 100% A, linearly decreasing to 10% A in 8 min, to 100%
A in 16 min, and held at 100% A for 23 min. The injection vol-
ume was 40  l. The UV detector was set at 214 nm.
Proteolytic Activity of SARS-3CLPro by Fluorogenic
Substrate Peptide Assay
The development of a fluorescent protease activity assay has
been reported previously (7). The enhanced fluorescence due
to cleavage of the fluorogenic substrate peptide (Dabcyl-
KTSAVLQSGFRKME-Edans) catalyzed by the protease
was monitored at 538 nm with excitation at 355 nm using a
fluorescence plate reader (Fluoroskan Ascent from
ThermoLabsystems, Sweden). The fluorimetric assay was
used to determine the IC50 of identified inhibitors on SARS
3CLPro activity. The protease was stored in the buffer contain-
ing 12 mM Tris–HCl (pH 7.5), 120 mM NaCl, 0.1 mM EDTA,
7.5 mM 2-mercaptoethanol and 1 mM dithiothreitol (DTT)
at  70 C before use.
Results
Screening of a 720 Compound Library Against 3CLPro
Activity by HPLC Assay
The spectrum collection, a library of 720 drugs and natural
products, was screened for 3CLPro inhibitory activity. A flow-
chart of the screening procedure is shown in Fig. 1. Initially,
10 different compounds were pooled, and the 72 mixtures
were then tested for their inhibitory activities against SARS-
3CLPro. The HPLC assay was used in the primary screening
because many compounds in the library are chromogenic.
Single compounds in the positive pools were then evaluated
for their activities. Two compounds, tannic acid and TF2B,
were found to be active against 3CLPro (Fig. 2). Tannic acid is
a water-soluble polyphenol present in plant food such as tea,
red wine, beer and nuts. In addition, tea polyphenols and many
tannin components are thought to be anticarcinogenic (14,15).
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Figure 2. Inhibition of 3CL Pro activity by HPLC assay. Injection of 40  l of
incubation samples for C18 reverse phase column analysis. The substrate or
product fragment peaks were analyzed by HPLC with UV absorbance detec-
tion at 214 nm. The HPLC system is described in Methods.
Table 1. Inhibition of SARS 3CLPro activity by natural products
Compound library IC50 ( M)
3-Isotheaflavin-3-gallate (TF2B) 7
Tannic acid 3
Tea extract IC50 ( g/ml)
Oolong tea 125
Green tea 125
Black tea 70
Puer tea 25
Other compositions in green tea IC50 ( M)
Caffeine 100
Theophylline 100
Catechin (C) 100
Epigallocatechin (EGC) 100
( )-Epigallocatechin gallte (EGCg) 100
Epicatechin (EC) 100
Epicatechin gallate (ECg) 100
Theaflavin composition in black tea IC50 ( M)
Theaflavin (TF1) 56
Theaflavin-3-gallate, TF-2a and 43
Theaflavin-3 -gallate, TF-2b mixture (TF2)
Theaflavin-3,3 -digallate (TF3) 9.5Evaluation of Tea Extracts and Pure Components from
Teas for Their Inhibition of 3CLProActivity
Since many other polyphenols related to tannic acid and TF2B
are also present in various kinds of teas, we decided to examine
the inhibition of activity by various tea extracts and several
well known pure ingredients present in teas. Thus, water
extracts from different types of teas were prepared and evalu-
ated for their inhibitory activities against 3CLPro. As shown in
Table 1, extracts from black and Puer teas inhibited 3CLPro
activity while those from green or oolong teas did not. We
further tested the possible involvement of several known ingre-
dients present in teas, including caffeine, theophylline, catechin
(C), epigallocatechin (EGC), ( )-epigallocatechin gallte
(EGCg), epicatechin (EC), epicatechin gallate (ECg), TF1,
TF2, TF2B, tannic acid and TF3. As shown in Table 1, the
results showed that methylxanthine (caffeine and theophylline)
did not influence 3CLPro activity; catechins, including C, EC,
ECg, EGC and EGCg, present in green tea (unfermented) and
oolong tea (partial fermented) also did not inhibit 3CLPro activ-
ity. Our results indicated that tannic acid, TF2B and TF3 are
3CLPro inhibitors as revealed by the fluorogenic substrate assay
(Fig. 3). TF2A was not tested because of its unavailability.
TF2B and TF3 as Potent Agents Against 3CLPro
Inhibitory Activity
The natural product screened library consisted of simple and
complex oxygen heterocycles, alkaloids, sequiterpenes, diter-
penes, pentacyclic triterpenes, sterols and many other diverse
representatives. Numerous black tea polyphenols (especially
those of TF1, TF2 and TF3) were found to inhibit 3CLPro. In
black tea, TF3 was the most abundant (1.05%) followed by
TF2A (0.34%), TF2B (0.11%) and TF1 (0.08%) (16). It is
interesting to note that TF3 contained two gallate groups
attached to the 3,3  positions as shown in Fig. 4b. TF2A and
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Figure 3. Inhibition of 3CLPro activity by fluorogenic substrate peptide assay. Inhibition of 3CLPro activity by tannic acid, TF1, TF2B, TF3 and EGCg. The
enhanced fluorescence due to cleavage of the fluorogenic substrate peptide catalyzed by the protease was monitored at 538 nm with exicitation at 355 nm using
a fluorescence plate reader. The determining assay is described in Methods.TF2B, on the other hand, consisted of only one gallate group
attached either to the 3 or the 3  positions, respectively
(Fig. 4b). In contrast, no gallate group was attached to TF1.
Results in Table 1, indicating that the gallate group attached to
the 3  position to TF2B and TF3, might be important for inter-
action with the 3CLPro active site. EC, EGCg, ECG and EGC
were much less active (IC50   100  M) than theaflavins.
Discussion
Human coronaviruses (HCoVs) are major causes of upper
respiratory tract illness in animals including humans. It has been
demonstrated that a novel coronavirus causes SARS. The main
protease, frequently called 3C-like protease (3CLPro), has been
identified as an attractive drug target (17). Of the 720 natural
products screened in this study, tannic acid (Fig. 4a) and TF2B
were identified using the HPLC proteolytic assay to inhibit 50%
of the proteolytic acitivity of 3CLPro at concentrations  10  M.
Both tannic acid and TF2B belong to the group of natural
polyphenols found in teas. Low concentrations of tannic acid
were found to inhibit proteases including tissue-type plasmino-
gen activator, urokinase-type plasminogen activator and plasmin
activity [13]. Over 300 different kinds of tea are now produced,
but they are classified into three main forms: green tea is
manufactured by drying fresh tea leaves, with emphasis on the
prevention of oxidation of the tea polyphenols during the manu-
facturing process. In contrast, the manufacture of black tea is
characterized by a high degree of fermentation, which produces
a series of chemical condensations among the ingredients present
in tea. Oolong tea is partially fermented, and the tea composi-
tions are more similar to those found in green tea (18). In evalu-
ating different types of tea, we found that extracts from several
different types of tea, including Puer and black tea, could inhibit
3CLPro activity while green or oolong tea could not. However, the
chemical composition in Puer tea is very complex and it is diffi-
cult to isolate pure ingredients for structural identification.
Purification and identification of Puer tea ingredients should be
carried out in a separate study.
We next examined whether other well-known ingredients
present in tea could also inhibit 3CLPro activity. We found
that methylxanthine (caffeine and theophylline) and catechins
(EGCg, EC, C, ECg and EGC) were not able to inhibit 3CLPro
activity at concentrations up to 100  M (Table 1). However,
TF1, TF2 and TF3 were more potent 3CLPro inhibitors than
catechins in green tea. During the fermentation step in the
production of black tea, most of the catechins are oxidized
and condensed into theaflavins through dimerization and
into thearubigins through polymerization. Green tea contains
 30% of catechins (dry mass base) while black tea contains
 9% of catechins and 4% of theaflavins (19). In another study,
Leung et al. (16) reported that TF3 was the most abundant
(1.05%) theaflavin in black tea followed by TF2A (0.34%),
TF2B (0.11%) and TF1 (0.08%). Tannic acid is a class of
polyphenolic in plants but the quantification of its levels in
green or black tea is difficult because tannic acid constitutes a
wide range of polymers with mol. wts of 500–3000 Da.
It is interesting to note that TF2B and TF3 are more potent
inhibitors of 3CLPro than TF1 (Table 1). Unlike TF2B and TF3,
TF1 does not contain a gallate group (Fig. 4b). Thus, the addi-
tion of a gallate group attached at the 3  position to TF2B and
TF3 might be important for their inhibitory activity against
3CLPro. These results suggest that TF2B and TF3 might be
good starting points for the design of more active inhibitors for
the 3CLPro encoded by SARS-CoV.
Finally, this study has identified three compounds (TF2B,
TF3 and tannic acid) that are effective 3CLPro inhibitors
(IC50  10  M). These compounds are abundant in the extract
of black tea (16,19). Black tea is a popular beverage in the
world. Results from this study warrant further investigation to
examine the effect of these natural products in inhibition of
SARS-CoV replication in cell culture. Clark et al. reported that
theaflavins extracted from black tea were able to neutralize
eCAM 2005;2(2) 213
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Figure 4. Chemical structures of tannic acid, catechins and TFs.bovine coronavirus and rotavirus infections (20). Thus, it will
be very interesting to evaluate, in a separate study, whether
drinking black tea can prevent or alleviate the infection of an
enteric form of coronavirus since SARS-CoV is known to
actively replicate in the intestinal tract (21).
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